Q-omics provides the consensus-scored RNA5SP163 profile across patient tissues and cancer cell-line models. RNA5SP163 expression is associated with patient survival in 4 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RNA5SP163 is differentially expressed in 2, with the highest sampling consensus in CHOL. Additionally, RNA5SP163 RNA expression shows 6,629 significant gene co-expression associations, with the highest sampling consensus in LIHC. Together, these results highlight KIRC, CHOL, and LIHC as cancer lineages where RNA5SP163 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNA5SP163 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNA5SP163 survival associations across molecular data types. RNA5SP163 RNA expression shows survival associations in the most cancer types (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNA5SP163 RNA expression–survival associations across cancer types. High RNA5SP163 expression shows unfavorable associations in KIRC, CHOL, PAAD and STAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .005). Together, the overview and detailed table identify KIRC as the clearest survival context for RNA5SP163 RNA expression.
This table summarizes RNA5SP163 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RNA5SP163. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNA5SP163 shows lower tumor expression in CHOL and KIRC. The CHOL box plot shows higher RNA5SP163 RNA expression in normal versus tumor tissue (log2 FC = −1.771, t-test p < 0.001).
This table shows molecular features associated with RNA5SP163 in patient tissues and cancer cell lines. In patient samples, RNA5SP163 shows the broadest associations at the RNA and protein expression levels, with LIHC recurring as the lineage with the largest associated feature set.
